Navigation Links
Study points to essential role of IL-22 in lung repair after the flu

Philadelphia, PA, March 11, 2013 Once the initial episode of influenza has passed, the chronic effects tend to be overlooked. The results of a new study indicate that the cytokine interleukin-22 (IL-22) plays a critical role in normal lung repair following influenza infection. This study is published in the April 2013 issue of the American Journal of Pathology.

"With the increasing prevalence of more infective and/or virulent strains of influenza, understanding the impact of virus on the host epithelium and the processes involved in lung repair are of great importance," says John F. Alcorn, PhD, an immunologist affiliated with the department of pediatrics at the Children's Hospital of Pittsburgh of UPMC. He notes that the findings open up new possibilities for developing therapeutic agents that promote recovery of normal lung function and architecture after influenza infection and lessen the likelihood of secondary infections. "A key finding is that even after the resolution of infection, influenza results in lung parenchymal remodeling that may be critical to susceptibility to further injury," says Dr. Alcorn.

This series of experiments used 6- to 8-week-old wild-type (WT) mice (C57BL/6 strain) as well as IL-22deficient mice, infected with influenza A PR/8/34 H1N1 or control vehicle. To determine the distribution of IL-22 in the lung, they used immunohistochemistry for the high affinity IL-22Ra1 receptor. Investigators found that in WT mice not inflected with influenza, IL-22 receptors were distributed on epithelial cells of the large and small airways, but not within the parenchyma. They noted that this receptor distribution suggests that in the absence of lung injury, IL-22 interacts mainly with the bronchial epithelial cells.

By 21 days post influenza infection, IL-22 receptors were observed in parenchymal tissue in injured areas, such as alveoli under repair. Researchers suggest that the IL-22 receptor can be upregulated at sites of influenza-associated injury.

The investigators also reported that 10 days after influenza infection, IL-22deficient mice showed significantly more severe damage and greater lung edema than WT control mice, as indicated by higher lactate dehydrogenase levels and more total protein content in bronchoalveolar lavage. No differences were found in viral load. Another indication of more severe lung injury was an increase in the number of lymphocytes in the IL-22deficient animals.

IL-22deficient mice also showed functional impairments. For instance, those infected with influenza showed significantly decreased compliance (referring to lung distensibility) and increased hysteresis (referring to compliance differences during inspiration and expiration), indicating lung stiffness. Histological examination 21 days after influenza infection showed that IL-22deficient mice displayed regions of diffuse inflammation and alveolar injury, few areas of metaplasia, higher intimal thickening, proteinaceous accumulation, and increased collagen deposition compared to WT mice. Gene expression analysis revealed aberrant expression of epithelial genes involved in repair processes in the mice lacking IL-22.

"The role of IL-22 in promoting epithelial repair is emerging. We demonstrate that IL-22 plays a critical role in regulating pulmonary epithelial repair responses during influenza infection and resolution," says Dr. Alcorn. IL-22 is currently under development as a potential therapeutic in human clinical trials.


Contact: David Sampson
Elsevier Health Sciences

Related biology news :

1. Intermountain study finds length of DNA strands can predict life expectancy
2. Genetic study of house dust mites demonstrates reversible evolution
3. Bats not bothered by forest fires, study finds
4. International study: Excess dietary salt may drive the development of autoimmune diseases
5. Study pinpoints, prevents stress-induced drug relapse in rats
6. Assembling the transcriptome of a noxious weed: New resources for studying how plants invade
7. Study uncovers enzymes double life, critical role in cancer blood supply
8. Study maps human metabolism in health and disease
9. Volcanic aerosols, not pollutants, tamped down recent Earth warming, says CU-Boulder study
10. Study provides insights into plant evolution
11. New study reveals how sensitive US East Coast regions may be to ocean acidification
Post Your Comments:
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... , September 28, 2015 ... expected to reach USD 12.03 billion by 2020, growing ... Technological advancements such as Backside Illumination (BSI) technique to ... over the forecast period.      (Logo: ... of the chip to reduce loss and, thus, reduce ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... Mass. , Oct. 13, 2015 Applied ... methodologies at critical decision points throughout the drug invention ... QSP Congress Boston 2015 on October 20-22, 2015 in ... Burke , PhD, Co-Founder, President, and CEO of Applied ... discovery from early research to clinical trials" on Wednesday ...
(Date:10/13/2015)... PARK, N.J. and SAN DIEGO ... (BASF) and Mast Therapeutics, Inc. have agreed to collaborate ...  Currently, excipient-grade poloxamer 188 NF, marketed by BASF under ... used in a variety of pharmaceutical and biological applications, ... Poloxamer 188 is the starting material for Mast,s lead ...
(Date:10/13/2015)... and TORONTO , Oct. 13, 2015 /PRNewswire/ ... that it has entered into a non-binding Letter of Intent ... Israeli company that has developed a proprietary cooling technology designed ... varicoceles. the United States and ... the ages of 25 and 44 diagnosed as infertile.  For ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... is excited to announce their partnership with the Keck Medicine of the ... chronic pain. , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking ...
Breaking Biology Technology: